rs116573957 - TOMM22P6 - LINC01192
Magnitude 2.8 · 1 study on file
Reported associations
-
A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients - Unknown journal (n.d.) · Unknown authors · PubMed 36210801
ABSTRACT: Diversity in pharmacogenomic studies is poor, especially in relation to the inclusion of black African patients. Lack of funding and difficulties in recruitment, together with the requirement for large sample sizes because of the extensive genetic diversity in Africa, are amongst the factors which have hampered pharmacogenomic studies in Africa. Warfarin is widely used in sub-Saharan Africa, but as in other populations, dosing is highly variable due to genetic and non-genetic factors. In order to identify genetic factors determining warfarin response variability, we have conducted a genome-wide association study (GWAS) of plasma concentrations of warfarin enantiomers/metabolites in sub-Saharan black-Africans. This overcomes the issue of non-adherence and may have greater sensitiv
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
warfarin pharmacogenomics based on rs116573957 Moderate
rs116573957 is associated with altered S-6-hydroxywarfarin metabolism; variant status may inform warfarin dosing
If prescribed warfarin, discuss variant status and potential need for pharmacogenomic-guided dosing with clinician